Dr Reddy’s Laboratories has launched valganciclovir tablets USP 450 mg, a therapeutic equivalent generic version of Valcyte (valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (FDA).
The Valcyte (valganciclovir) tablets brand had US sales of approximately $440 million MAT for the most recent twelve months ending in October 2014 according to IMS Health.
Dr Reddy’s valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.